comparemela.com

Latest Breaking News On - Tyr pharma company profile - Page 2 : comparemela.com

55,857 Shares in aTyr Pharma, Inc. (NASDAQ:LIFE) Bought by Pale Fire Capital SE

Pale Fire Capital SE bought a new stake in aTyr Pharma, Inc. (NASDAQ:LIFE – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 55,857 shares of the biotechnology company’s stock, valued at approximately $88,000. Pale Fire Capital […]

United-states
Canada
Atyr-pharma-inc
Tyr-pharma-company-profile
Nasdaq
Securities-exchange-commission
Topco-ltd
Sigma-securities
Royal-bank
Pale-fire-capital
Tyr-pharma

aTyr Pharma, Inc. (NASDAQ:LIFE) Receives $20.75 Consensus PT from Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year […]

United-states
Alyeska-investment-group
Tyr-pharma-company-profile
Stonepine-capital-management
Atyr-pharma-inc
Samsara-biocapital
Nasdaq
Blackrock-inc
Tyr-pharma
Get-free-report
Capital-management

Brokerages Set aTyr Pharma, Inc. (NASDAQ:LIFE) Target Price at $20.75

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price […]

United-states
American
Sigma-securities
American-century-companies-inc
Atyr-pharma-inc
Tyr-pharma-company-profile
Squarepoint-ops
Nasdaq
Virtu-financial
Tyr-pharma
Get-free-report

aTyr Pharma (NASDAQ:LIFE) Downgraded by StockNews.com

StockNews.com lowered shares of aTyr Pharma (NASDAQ:LIFE – Free Report) from a hold rating to a sell rating in a research note released on Saturday morning. Separately, HC Wainwright reaffirmed a buy rating and issued a $35.00 price objective on shares of aTyr Pharma in a research report on Thursday, September 21st. One research analyst […]

United-states
American
Tyr-pharma-company-profile
Capital-partners
Sigma-securities
Squarepoint-ops
American-century-companies-inc
Atyr-pharma-inc
Tyr-pharma
Free-report
Moderate-buy

aTyr Pharma, Inc. (NASDAQ:LIFE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among […]

United-states
Tyr-pharma-company-profile
Capital-partners
York-mellon-corp
Hermes-inc
Virtu-financial
Nasdaq
Atyr-pharma-inc
Charles-schwab-investment-management-inc
Tyr-pharma
Get-free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.